Compare VVOS & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | NDRA |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.5M |
| IPO Year | 2020 | 2016 |
| Metric | VVOS | NDRA |
|---|---|---|
| Price | $0.41 | $4.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.75 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 151.7K | 18.9K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.76 | ★ 84.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,443,000.00 | N/A |
| Revenue This Year | $69.66 | N/A |
| Revenue Next Year | $48.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.05 | N/A |
| 52 Week Low | $0.36 | $2.96 |
| 52 Week High | $5.21 | $9.83 |
| Indicator | VVOS | NDRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 41.44 |
| Support Level | $0.37 | $3.27 |
| Resistance Level | $0.55 | $4.90 |
| Average True Range (ATR) | 0.03 | 0.42 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 48.17 | 9.64 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.